Hep C Estimates Could Be Way Off
Knowing how common a certain condition is can help prepare health care systems to treat patients. But the estimates for one disease may be way off.
Trio Treatment Showed Promise for Hep C
Three may be a crowd when it comes to company, but it might be an ideal number when it comes to medication for treating hepatitis C.
Cirrhosis Survival Spiked
Good news for cirrhosis patients: Survival may be much more common than it once was.
This Rx Combo Fought Hep C
Hepatitis C patients may soon have another medication option.
Hepatitis C Treatment Granted Breakthrough Designation
KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic HCV genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis. Additionally, the company announced presen...
New Warnings for Hepatitis C Rx
Taken with a heart medication, two hepatitis C drugs might pose some serious health risks.
When Delaying Treatment Could Cost You More Dough
The cost of treating a chronic disease can add up, sometimes leading patients to hold off until the disease progresses. The most cost-effective way to treat a common liver condition, however, might be to face it head on.
No Shortage of Hepatitis C Treatments
In the last three years, there have been many advances in treating hepatitis C, which can not only offer patients more treatment options but also shorter treatment times.
Experimental Rx May Cure Hepatitis C in Six Weeks
Achillion Pharmaceuticals Inc. announced today that its experimental hepatitis C treatment may be able to reverse hepatitis C in as little as six weeks.
Achillion Achieves 100% SVR12 in Phase 2 Trial
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced updated interim results from the ongoing interferon-free, ribavirin-free, Phase 2 study to evaluate the efficacy, safety, and tolerability of six weeks of 50 mg of ACH-3102 and 400 mg of sofosbuvir, a marketed nucleotide polymerase inhibitor, in treatment-naïve genotype 1 HCV-infected patients.